HMGA2: A Biomarker in Gynecologic Neoplasia.

Abstract

High Mobility Group A2 gene (HMGA2), an oncofetal protein, is normally expressed in fetal development and completely shuts down in almost all organs and tissue types during adulthood. It is upregulated or overexpressed again in certain mesenchymal neoplasms due to chromosomal translocations and in malignant epithelial tumors through transcription regulation. HMGA2 overexpression can either drive tumor development or promote the aggressiveness of tumor growth. Many gynecologic neoplasms, including uterine smooth muscle tumors and ovarian cancer, are associated with HMGA2 overexpression. In this article, we review recent developments in the study of HMGA2 and its expression as a potential biomarker for gynecologic neoplasms and clinic application.

• Authors: Jian-Jun Wei
• Journal: Journal of clinical and translational pathology (J Clin Transl Pathol) Vol. 2 Issue 1 Pg. 3-7 ( 2022) ISSN: 2771-165X [Electronic] United States
• PMID: 35340777 (Publication Type: Journal Article)